<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03638882</url>
  </required_header>
  <id_info>
    <org_study_id>I2P2-2-00140</org_study_id>
    <nct_id>NCT03638882</nct_id>
  </id_info>
  <brief_title>Cognitive Reserve and Second Language Acquisition</brief_title>
  <official_title>Boosting Cognitive Reserve Through Adult Second Language Acquisition With Duolingo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rotman Research Institute at Baycrest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rotman Research Institute at Baycrest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bilingualism has been shown to have a strong protective effect against dementia, delaying the
      diagnosis of Alzheimer's disease by up to 4 years. The purpose of the study is to test
      whether learning a second language using Duolingo software could improve cognitive functions
      in older adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a 3-arm, randomized controlled trial. The primary objective of the study is to
      test the impact of second language acquisition through short-term use of the Duolingo app on
      cognitive functioning, particularly executive function in older adults compared to a brain
      training application.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in working memory, n-back</measure>
    <time_frame>change from baseline to 16 weeks</time_frame>
    <description>Working memory assessed by the n-back test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in inhibitory Control, Simon task</measure>
    <time_frame>change from baseline to 16 weeks</time_frame>
    <description>Inhibitory control assessed by the Simon task</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in inhibitory Control, DKEFS</measure>
    <time_frame>change from baseline to 16 weeks</time_frame>
    <description>DKEFS Colour Word Interference</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in attention abilities</measure>
    <time_frame>change from baseline to 16 weeks</time_frame>
    <description>Attention assessed by the Test of Everyday Attention (TEA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in language abilities</measure>
    <time_frame>change from baseline to 16 weeks</time_frame>
    <description>Winterlight designed battery assessing paragraph reading and recall, picture description and object naming.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change in verbal fluency</measure>
    <time_frame>change from baseline to 16 weeks</time_frame>
    <description>semantic and phonological fluency tasks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>executive function assessed by trailmaking test</measure>
    <time_frame>change from baseline to 16 weeks</time_frame>
    <description>Trails B implemented on tablet</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Spanish Proficiency (Duolingo group only)</measure>
    <time_frame>change from baseline to 16 weeks</time_frame>
    <description>WebCAPE Online Spanish Test</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Executive Function</condition>
  <arm_group>
    <arm_group_label>Duolingo Spanish Course</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30 minutes each day, 5 days a week for 16 weeks. Total of 40 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BrainHQ</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 minutes each day, 5 days a week for 16 weeks. Total of 40 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Passive Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>No intervention.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Duolingo</intervention_name>
    <description>Will learn Spanish using the commercially available Duolingo application. It is a computerized language training program.</description>
    <arm_group_label>Duolingo Spanish Course</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>BrainHQ</intervention_name>
    <description>Will use the commercially available Posit Science product Brain HQ. Brain HQ is a computerized adaptive cognitive brain training program.</description>
    <arm_group_label>BrainHQ</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Passive Control</intervention_name>
    <description>No Intervention.</description>
    <arm_group_label>Passive Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must have normal vision and hearing.

          -  Participants must be able to travel to Baycrest by personal or study-arranged
             automobile, or public transportation.

          -  Participants must be monolingual native English speakers.

          -  Participants must be willing to provide informed consent.

          -  Participants must have daily access to a smartphone/mobile device.

          -  Have not previously studied Spanish formally, nor any other language in the past 10
             years.

        Exclusion Criteria:

          -  have a neurological disorder.

          -  meet DSM-IV-TR criteria for Axis I mood, anxiety, or psychotic or substance abuse
             disorders.

          -  Fluent in more than one language.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jed Meltzer, Ph.D.</last_name>
    <phone>416-785-2500</phone>
    <phone_ext>2117</phone_ext>
    <email>jmeltzer@research.baycrest.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baycrest Health Sciences</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M6A 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jed Meltzer, Ph.D.</last_name>
      <phone>416-785-2500</phone>
      <phone_ext>2117</phone_ext>
      <email>jmeltzer@research.baycrest.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 4, 2018</study_first_submitted>
  <study_first_submitted_qc>August 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2018</study_first_posted>
  <last_update_submitted>September 18, 2019</last_update_submitted>
  <last_update_submitted_qc>September 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Rotman Research Institute at Baycrest</investigator_affiliation>
    <investigator_full_name>Jed A. Meltzer, Ph.D</investigator_full_name>
    <investigator_title>Neurorehabilitation Scientist</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

